Genetic predisposition to prostate cancer: an update.

Area of Science:

• Genetics
• Oncology
• Genomic Medicine

Background:

• Advances in DNA sequencing and genome-wide association studies (GWAS) have illuminated the role of genetic variation in prostate cancer (PrCa) risk.
• Both high-risk predisposition genes and common low-moderate risk variants contribute significantly to familial PrCa risk, collectively explaining over one-third of cases.
• Identifying individuals with genetic predispositions or family history is clinically vital due to associations with earlier onset and poorer outcomes.

Purpose of the Study:

• To review rare and common germline genetic variations implicated in hereditary and familial prostate cancer.
• To discuss the clinical utility of genetic testing and risk scores in prostate cancer screening and risk stratification.
• To explore ongoing research into targeted screening strategies for high-risk populations.

Main Methods:

• Review of existing literature on genetic variations and prostate cancer risk.
• Analysis of data from genome-wide association studies (GWAS).
• Discussion of current research on targeted screening approaches.

Main Results:

• Published single nucleotide polymorphisms (SNPs) explain approximately 38% of familial PrCa risk.
• Men in the top 1% of genetic risk profiles show a 5.71-fold increased risk of developing prostate cancer.
• Around 170 prostate cancer susceptibility loci have been identified in European populations, with a need for data in non-European cohorts.

Conclusions:

• Genetic factors play a substantial role in prostate cancer susceptibility, necessitating further research into their clinical application.
• Targeted screening strategies for high-risk men, informed by genetic profiles, are under investigation and show promise.
• Genetic testing and risk scores offer potential for improved prostate cancer screening and risk stratification, pending further validation, especially in diverse populations.